Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 2
Submit an article Journal homepage
803
Views
39
CrossRef citations to date
0
Altmetric
Original Article

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

Martin R. Farlow Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USACorrespondence[email protected]
,
Gus Alva ATP Clinical Research, Costa Mesa, CA, USA
,
Xiangyi Meng Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
&
Jason T. Olin Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Pages 263-269 | Accepted 23 Oct 2009, Published online: 24 Nov 2009

References

  • Exelon capsules (rivastigmine). Prescribing information. January 2009. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf. Last accessed 17 September 2009
  • Birks J. Cholinesterase inhibitors for Alzheimer’s disease (Review). Cochrane Database Syst Rev 2006;CD005593.doi: 10.1002/14651858
  • Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease (Review). Cochrane Database Syst Rev 2009;CD001191.doi: 10.1002/14651858
  • Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opin Drug Saf 2004;3:425-40
  • Lefevre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008;83:106-14
  • Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69(4 Suppl 1):S14-22
  • Sadowsky CH, Dengiz A, Olin J, et al. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease. Am J Alzheimer Dis Other Demen 2009;24:267-75
  • Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2009;Aug 10.doi: 10.1002/gps.2355
  • Oertel W, Ross JS, Eggert K, Adler G. Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007;69(4 Suppl 1):S4-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.